Host Immunoglobulin E specific for xenogeneic epitopes on F(ab')2 antivenom (Anti-F(ab')2 IgE)

Host IgE specific for xenogeneic epitopes on F(ab')2 antivenom refers to the population of immunoglobulin E antibodies produced by a patient that recognize foreign protein structures within antivenom preparations, typically derived from equine (horse) or ovine (sheep) sources (WHO, 2018). These antibodies are the primary mediators of immediate (Type I) hypersensitivity reactions, including life-threatening anaphylaxis, which can occur upon administration of antivenom to treat envenomation (Leon et al., 2008). The IgE molecules bind to the foreign F(ab')2 fragments or contaminating serum proteins, triggering the degranulation of mast cells and basophils and the subsequent release of inflammatory mediators like histamine (Stone et al., 2014). While antivenom is essential for neutralizing venom toxins, the presence of these specific IgE antibodies poses a significant therapeutic challenge, often requiring premedication with antihistamines and corticosteroids or rapid desensitization protocols. In modern clinical practice, drugs like Omalizumab may be used off-label to neutralize these IgE antibodies in highly sensitized individuals, while Epinephrine remains the first-line treatment for the resulting anaphylactic symptoms (PubChem; NIH).

Other names

Anti-antivenom IgEAnti-equine IgEAnti-ovine IgESpecific IgE to horse serum proteinsSpecific IgE to sheep serum proteinsHost IgE specific for F2 antivenom fragments

Neutralization of circulating IgE to prevent binding to high-affinity FcεRI receptors on mast cells and basophils, thereby inhibiting the release of inflammatory mediators during antivenom administration.